Full-scale Intervention Study: Genetic Risk Communication and Wearables

Type 2 Diabetes Clinical Trial

Official title:

Combined Effects of Communicating Genetic Risk of Type 2 Diabetes and Wearable Technologies On Objectively Measured Behavioral Outcomes in Overweight or Obese East Asian Individuals.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05524909
• Other study ID #: geneticriskwearabletrial_full
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: December 2023
• Source: The University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Communication of information about risk of type 2 diabetes (T2D) alone has not been associated with changes in habitual behaviors among individuals of European ancestry. In contrast, the use of wearable devices that monitor physical activity (PA) has been associated with changes in behavior in some studies. It is uncertain whether risk communication might enhance the effects of wearable devices. We aim to assess the effects on wearable-device-measured PA of communicating genetic risk for T2D alone or in combination with goal setting and activity prompts from a wearable device among overweight or obese East Asians.

Methods: In a parallel group, randomized controlled trial, a total of 355 overweight or obese East Asian individuals aged 40-60 years will be allocated into one of three groups: 1 control and 2 intervention groups. Blood samples will be used for estimation of T2D genetic risk and analysis of metabolic risk markers. Genetic risk of T2D will be estimated based on 113 SNPs associated with T2D among East Asians using an established method. All three groups will receive a Fitbit device. Both intervention groups will be given T2D genetic risk estimates along with lifestyle advice, but one of the intervention groups will additionally use Fitbit's step-goal setting and prompt functions. Questionnaires and physical measurements will be administered at baseline, immediately after intervention delivery, and 6 and 12-month post-intervention following standard operating procedures. The primary outcome is time spent in moderate-to-vigorous PA measured through the Fitbit. Secondary outcomes include other parameters of wearable-device-measured PA, sedentary time, and sleep, body mass index, systolic and diastolic blood pressure, five intermediate metabolic risk markers, hand grip strength, self-reported PA, self-reported fruit and vegetable consumption and smoking status, and a list of psychological variables.

Discussion: This study will be the first randomized controlled trial using the combination of communication of T2D genetic risk with standard functions of wearable devices in any population. Findings will inform strategies to prevent T2D through lifestyle modification.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 355
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

• East Asian ancestry

• Aged 40-60 years

• overweight or obese (i.e. measured BMI =23 kilograms/meters2 according to the WHO BMI-defined cut-offs for Asians)

• Able to perform daily-living physical activity

Exclusion Criteria:

• have been diagnosed with any type of diabetes

• pregnant or lactating

• unable to perform daily-life physical activities (determined through Physical activity Readiness Questionnaire [PAR-Q])

• participating in another research study or exercise programs

• had experience of genetic testing

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Exercise
• Fitness Trackers
• Genetic Predisposition to Disease
• Physical Activity
• Type 2 Diabetes

Intervention

Genetic:
• Genetic Risk Estimate
The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).

Device:
• Genetic Risk Estimate + Fitbit Functions
The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate.

Locations

Country	Name	City	State
Hong Kong	Exercise Physiology Lab, The University of Hong Kong	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Moderate to Vigorous Physical Activity Minutes between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	Moderate to Vigorous Physical Activity Minutes (per day) will be objectively measured by the Fitbit tracker.	Baseline, 12-month post-intervention, 6-month follow-up
Secondary	Changes in body mass index (BMI) between baseline and 6-month follow-up	Measured height (in meters) and body weight (in kilograms) will be combined to report BMI in kg/m^2	Baseline and 6-month follow-up
Secondary	Changes in systolic blood pressure between baseline and 6-month follow-up	Systolic blood pressure (mm Hg) will be measured using the OMRON HEM-907 Digital Automatic Blood Pressure Monitor.	Baseline and 6-month follow-up
Secondary	Changes in diastolic blood pressure between baseline and 6-month follow-up	Diastolic blood pressure (mm Hg) will be measured using the OMRON HEM-907 Digital Automatic Blood Pressure Monitor.	Baseline and 6-month follow-up
Secondary	Changes in hand grip strength between baseline and 6-month follow-up	Hand grip strength (in kilograms) will be measured using the Jamar Hydraulic Hand Dynamometer, which has good reliability and reproducibility.	Baseline and 6-month follow-up
Secondary	Changes in Hemoglobin A1c (HbA1c) between baseline and 6-month follow-up	Blood samples will be collected to test the five key biochemical markers of T2D and cardiovascular disease, including HbA1c (%).	Baseline and 6-month follow-up
Secondary	Changes in Total cholesterol between baseline and 6-month follow-up	Blood samples will be collected to test the five key biochemical markers of T2D and cardiovascular disease, including Total cholesterol (mmol/L).	Baseline and 6-month follow-up
Secondary	Changes in High-density lipoproteins (HDL) between baseline and 6-month follow-up	Blood samples will be collected to test the five key biochemical markers of T2D and cardiovascular disease, including HDL (mmol/L).	Baseline and 6-month follow-up
Secondary	Changes in Low-density lipoproteins (LDL) between baseline and 6-month follow-up	Blood samples will be collected to test the five key biochemical markers of T2D and cardiovascular disease, including LDL (mmol/L).	Baseline and 6-month follow-up
Secondary	Changes in Triglycerides between baseline and 6-month follow-up	Blood samples will be collected to test the five key biochemical markers of T2D and cardiovascular disease, including Triglycerides (mmol/L).	Baseline and 6-month follow-up
Secondary	Changes in Self-reported Physical Activity between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Fruit and Vegetable Consumption between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Smoking Status between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Psychological Status between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in five activity indicators (steps, 'sedentary minutes', 'lightly active minutes', calories burn, and sleep time)	steps, sedentary minutes, lightly active minutes, calories burn, and sleep time will be objectively measured by the Fitbit tracker.	Baseline, 12-month post-intervention, 6-month follow-up